Cancer Survival Rates Are Misleading

TL;DR

This paper explains that five-year cancer survival rates can be misleading indicators of treatment effectiveness or early detection benefits, emphasizing the need for mortality data and randomized trials.

Contribution

It demonstrates through a Markov model that survival statistics alone can be misleading, highlighting the importance of mortality outcomes and randomized trials for evaluating cancer screening and treatment.

Findings

High survival rates can occur even with ineffective treatments.

Survival improvements may not reflect actual reductions in mortality.

Five-year survival is insufficient for assessing treatment efficacy.

Abstract

Five-year cancer survival rates are widely reported and often interpreted to mean that early detection saves lives, that a late fatal diagnosis would have been prevented by earlier detection, and that increasing survival over time proves better treatment. This expository article explains why such inferences are not supported by survival statistics alone. A simple Markov model of tumor progression, calibrated to patterns like those in SEER data, shows that high survival after early diagnosis, large gaps between early and late stage, and improving survival can all appear even when treatment is ineffective and screening does not reduce mortality. The discussion ties these points to the clinical literature and argues that randomized trials and mortality outcomes are needed to support screening and treatment claims; five-year survival alone provides little actionable evidence and is easily misread.